Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib in advanced cancers
NCT02033148Phase 1Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Aug 2014
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of icotinib in solid tumor (advanced stage), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Pharmacokinetic parameters. Planned start Aug 2014; status: withdrawn.
02
Drugs
icotinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02033148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02033148.